Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Data solutionsForge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Index solutionsForge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Forge Thematic BasketsExplore focused views into key private market themesLiquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarEmerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary marketplace / Trade private companies / Buy and sell Iambic Therapeutics stock
Iambic Therapeutics

Iambic Therapeutics stock

$--
Register to buy and sell private company shares
For more details on financing and valuation of private companies similar to Iambic Therapeutics before its IPO, register or login today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Iambic Therapeutics stock price

Price history chart

7D
1M
3M
6M
1Y
All
Forge Price
$--
No longer available
Forge Price valuation
$--

Iambic Therapeutics stock FAQs

To buy and sell Iambic Therapeutics stock

Can you buy Iambic Therapeutics stock?

You can no longer buy Iambic Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

How to buy Iambic Therapeutics stock?

You can no longer buy Iambic Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

Can you sell Iambic Therapeutics stock?

You can no longer sell stock of Iambic Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

How to sell Iambic Therapeutics stock?

You can no longer sell stock of Iambic Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

To learn more about Iambic Therapeutics stock

Is Iambic Therapeutics a public company?

Iambic Therapeutics is now a public company traded on NASDAQ with ticker IAM.

What is Iambic Therapeutics’ stock price?

The stock price of Iambic Therapeutics is not currently available.

What is Iambic Therapeutics’ stock ticker symbol?

The ticker symbol of Iambic Therapeutics is IAM.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platforms for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Iambic Therapeutics funding rounds and valuation

Total funding $395.29M

Funding history chart

Funding round and deals details

Funding Date Round Amount Raised Price Per Share Post-Money Valuation 3 Key Investors
04/01/2026 Series B-4 $32.77M $3.26 $671.11M Undisclosed Investors
Price Per Share
$3.26
Shares Outstanding
10,052,045
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
11/10/2025 Series B-3 $119.27M $3.10 $557.23M Abingworth, Alexandria Venture Investments, Alumni Ventures Group, ARK Investments, Ascenta Capital, Catalio Capital Management, Everbright, Freeflow Ventures, Illumina Ventures, Mubadala Development Company, Pegasus Ventures, QIA, Regeneron, Sequoia Capital, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati
Price Per Share
$3.10
Shares Outstanding
38,473,957
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth, Alexandria Venture Investments, Alumni Ventures Group, ARK Investments, Ascenta Capital, Catalio Capital Management, Everbright, Freeflow Ventures, Illumina Ventures, Mubadala Development Company, Pegasus Ventures, QIA, Regeneron, Sequoia Capital, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati
06/18/2024 Series B-2 $65.35M $2.97 $382.7M Abingworth, Alumni Ventures Group, ARK Investments, Coatue Management, Exor Ventures, Illumina Ventures, Mubadala Development Company, Nexus Venture Partners, QIA, Tao Capital Partners
Price Per Share
$2.97
Shares Outstanding
21,994,473
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth, Alumni Ventures Group, ARK Investments, Coatue Management, Exor Ventures, Illumina Ventures, Mubadala Development Company, Nexus Venture Partners, QIA, Tao Capital Partners
10/03/2023 Series B $106.23M $2.48 $275.56M Abingworth, Alumni Ventures Group, Ascenta Capital, Bill Rastetter, Catalio Capital Management, Coatue Management, Freeflow Ventures, Gradiant Corporatoin, Illumina Ventures, Nexus Venture Partners, Nvidia Ventures, Orbimed, Sequoia Capital, Shanda Holdings, Tao Capital Partners
Price Per Share
$2.48
Shares Outstanding
42,904,185
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth, Alumni Ventures Group, Ascenta Capital, Bill Rastetter, Catalio Capital Management, Coatue Management, Freeflow Ventures, Gradiant Corporatoin, Illumina Ventures, Nexus Venture Partners, Nvidia Ventures, Orbimed, Sequoia Capital, Shanda Holdings, Tao Capital Partners
07/14/2021 Series A $67.15M $2.37 $173.61M Catalio Capital Management, Coatue Management, Freeflow Ventures, Nexus Venture Partners, Orbimed, Sequoia Capital
Price Per Share
$2.37
Shares Outstanding
28,295,040
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Catalio Capital Management, Coatue Management, Freeflow Ventures, Nexus Venture Partners, Orbimed, Sequoia Capital
07/14/2021 Series A-1 $2M $1.90 $173.61M Catalio Capital Management, Coatue Management, Freeflow Ventures, Nexus Venture Partners, Orbimed, Sequoia Capital
Price Per Share
$1.90
Shares Outstanding
1,053,462
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Catalio Capital Management, Coatue Management, Freeflow Ventures, Nexus Venture Partners, Orbimed, Sequoia Capital
04/01/2020 Series Seed $2.52M $0.35 $8.4M Freeflow Ventures, Nexus Venture Partners
Price Per Share
$0.35
Shares Outstanding
7,231,110
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Freeflow Ventures, Nexus Venture Partners

Company details

Iambic Therapeutics, based in San Diego, redefines drug discovery by combining human ingenuity with the power of AI. Emphasizing AI-driven design and automation, the company is a pioneer in creating data-efficient, physics-informed AI models. Iambic Therapeutics achieves more reliable and accurate modeling by incorporating physics principles into AI architectures, enabling deeper exploration in chemical space and accelerating the journey toward innovative medical solutions.
Founded
2019
Headquarters
San Diego, CA, United States
Leadership
Chao Zhang, Ph.D.
Chief Scientific Officer
Fred Manby, Ph.D.
Chief Technology Officer
Founder
Michael Secora
Chief Financial Officer
Neil Josephson
Chief Marketing Officer
Pete Olson
Chief Strategy Officer
Tabbert Teng
Vice President of Finance
Thomas Miller, Ph.D.
Chief Executive Officer
Founder
Board
Aaron Weiner
Board Member
Jishnu Bhattacharjee
Board Member
R. Jacob Vogelstein Ph.D
Board Member

Iambic Therapeutics news and media highlights

Independent news coverage

Iambic ups rhythm in AI-enabled race to clinic, revealing $100M round and Nvidia pact

Iambic Therapeutics is finding its rhythm, raising $100 million and partnering with the shovel seller of the artificial intelligence gold rush to advance a pipeline led by a pair of cancer candidates into the clinic. The San Diego-based biotech is built on technologies for predicting protein-ligand structures, generating molecular designs and other drug discovery tasks.

Explore private companies in the Healthcare Software sector

Sector: Healthcare
Subsector: Healthcare Software
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
AbridgeAbridge$200.00 +$30.00 (17.65%)$xx.xxSeries E$5.3B$158.48$315.93M
BenchlingBenchlingNot available$xx.xxSeries F$6.1B$32.70$89.62M
Collective HealthCollective Health$0.16 -$0.02 (11.11%)$xx.xxSeries F$1.53B$0.75$280M
CommureCommureNot available$xx.xxSeries D-3$7B$80.09$70M
Heidi HealthHeidi HealthNot available$xx.xxNot available------
Hippocratic AIHippocratic AINot available$xx.xxSeries C$3.5B$26.33$126M
OpenEvidenceOpenEvidenceNot available$xx.xxSeries D-2$13.45B$487.38$192.5M
PathosPathosNot available$xx.xxSeries E$3B$13.24$237M
Rad AIRad AINot available$xx.xxSeries C$527.53M$22.51$80.9M
Smarter TechnologiesSmarter TechnologiesNot available$xx.xxSeries B$341.85M$16.75$50M

Forge is your trusted partner to buy and sell Iambic Therapeutics stock

Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Oct 28, 2026

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar figure and percentage displayed indicate the change in the per-share Forge Price™ over the past six months, expressed in dollars and as a percentage, respectively.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.